-
Agilent completes acquisition of Genohm
biospectrumasia
May 16, 2018
This acquisition enhances Agilent’s current software portfolio
-
Lilly to acquire AurKa Pharma
biospectrumasia
May 16, 2018
Acquisition Expands Lilly Oncology Pipeline with Early-Phase Asset Being Studied in Multiple Tumor Types
-
Takeda clinches $62B deal to drugmaker Shire
biospectrumasia
May 09, 2018
The final deal is approximately 46 percent cash and 54 percent stock, leaving Shire shareholders owning around half of the combined group.
-
First-quarter acquisition activity lifts hopes for a big year
EvaluatePharma
April 24, 2018
In the annals of biopharma M&A the first quarter of 2018 will go down as another strong start to the year, with $34bn in deals achieved without the benefit of a single mega-merger.
-
Bliss GVS Pharma buys stake in Eco-rich Cosmetic India
expressbpd
April 23, 2018
The transaction was completed through its 70 per cent subsidiary, Kremoint Pharma
-
Luye strengthens presence in Singapore with NHC acquisition
biospectrumasia
April 11, 2018
Based in the heart of Singapore’s premier medical hub, Novena Heart Centre is one of the largest and fastest growing multi-disciplinary cardiology group practices in Singapore with plans to set up more clinics
-
ImmunoPrecise acquires ModiQuest for €7M
biospectrumasia
April 10, 2018
As a result of the acquisition of ModiQuest, ImmunoPrecise is now an innovative, integrated antibody solutions company focused on the next generation of technology behind therapeutic antibody discovery.
-
Roche completes Flatiron Health acquisition
biospectrumasia
April 10, 2018
Flatiron partners with more than 265 community cancer clinics, six major academic research centres, and 14 therapeutic oncology companies.
-
Novartis to buy AveXis for $8.7B
biospectrumasia
April 10, 2018
Novartis expects the acquisition to "strongly contribute" to core operating income and earnings per share.
-
LivaNova completes TandemLife acquisition
biospectrumasia
April 08, 2018
Under the terms of the agreement, LivaNova paid $200 million to TandemLife at closing with an additional $50 million to be paid based on specified regulatory milestones.